EFDID: 337837EFD: View Filing

Issuer: Akers Biosciences, Inc. (0001321834) - D

Accession: 0001493152-20-006006 (XMLRaw Data) (EDGAREDGAR Files) (Form DForm D)

EDGAR: Issuer Information
  • CIK:
    0001321834
  • Entity Name:
    Akers Biosciences, Inc.
  • Entity Type:
    Corporation
  • Jurisdiction:
    NEW JERSEY
  • Year of Inc:
    Over 5 years ago
  • Address:
    201 GROVE ROAD
    THOROFARE, NJ 08086
  • Persons:
    Related Persons 5
    Howard Yeaton
    Executive Officer 
    Interim Chief Financial Officer
    Christopher C. Schreiber
    Executive Officer, Director 
    Executive Chairman of the Board of Directors; Principal Executive Officer
    Joshua Silverman
    Director
    Bill J. White
    Director
    Robert C. Schroeder
    Director
EDGAR: Offering Information
  • Accession Date:
    04/07/2020
  • First Sale Date:
    03/23/2020
  • Offering Amount:
    $2,718,057
  • Amount Sold:
    $1,233,057
  • Amount Remaining:
    $1,485,000
  • Exemptions:
    Rule 506
  • Security Type(s):
    Equity
  • Sales Clarification:
    Upon the achievement of certain milestones, the Company shall issue an additional 750,000 shares of its common stock, equal to $1,485,000 of the above listed total offering amount.
EFD: Current State Notices

No State Notices found in EFD

EDGAR: Sales Compensation Recipient Information

There were no Sales Compensation Recipient Information associated with this Accession Number.

EDGAR: Signatures
IssuerSignatureSigner NameTitleSignatureDate
Akers Biosciences, Inc./s/ Howard YeatonHoward YeatonInterim Chief Financial Officer2020-04-07